Skip to content

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) in Patients With Refractory Epilepsy

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02474407
Enrollment
78
Registered
2015-06-17
Start date
2015-06-30
Completion date
2016-07-31
Last updated
2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Epilepsy

Keywords

Seizures, Epilepsy

Brief summary

This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)

Detailed description

To determine the bioavailability of diazepam nasal spray versus diazepam rectal gel (Diastat®) under conditions of use in adolescent and adult persons with epilepsy (PWE) meeting the definition of refractory epilepsy.

Interventions

DRUGdiazepam rectal gel

Sponsors

Acorda Therapeutics
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of refractory epilepsy * Body weight 26 to 111 kilogram (kg) inclusive * Other inclusion criteria apply

Exclusion criteria

* Male or female subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product * Female subject who is pregnant, breastfeeding, or planning to become pregnant * Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam * Other

Design outcomes

Primary

MeasureTime frameDescription
AUC 0-24h24 hoursRelative bioavailability based on area under time plasma concentration curve.
Cmax24 hoursRelative bioavailability based on maximum observed plasma concentration.

Secondary

MeasureTime frameDescription
Focused Nasal Exam (Part A)pre-dose (day 1) up to 24 hours post-doseA focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded none to Grade 4 septal perforation. Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Focused Nasal Exam (Part B)pre-dose (day 1) up to 24 hours post-doseA focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Smell Identification Test (SIT)day 1 up to day 31The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different scratch and sniff strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.
Taste Change QuestionnaireUp to 24 hoursQuestionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.

Countries

United States

Participant flow

Recruitment details

This is a randomized crossover study with 78 subjects total.

Participants by arm

ArmCount
All Participants
DZNS (Diazepam Nasal Spray) vs DRG (Diazepam rectal gel)
78
Total78

Baseline characteristics

CharacteristicAll Participants
Age, Categorical
<=18 years
2 Participants
Age, Categorical
>=65 years
1 Participants
Age, Categorical
Between 18 and 65 years
75 Participants
Age, Continuous41.4 years
STANDARD_DEVIATION 13.52
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
73 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
13 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
Race (NIH/OMB)
White
57 Participants
Region of Enrollment
United States
78 Participants
Sex: Female, Male
Female
51 Participants
Sex: Female, Male
Male
27 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 780 / 78
other
Total, other adverse events
60 / 7820 / 78
serious
Total, serious adverse events
0 / 780 / 78

Outcome results

Primary

AUC 0-24h

Relative bioavailability based on area under time plasma concentration curve.

Time frame: 24 hours

ArmMeasureValue (MEAN)Dispersion
Single Dose of Diazapam Nasal Spray (DZNS)AUC 0-24h1357.7 ng*h/mLStandard Deviation 802.78
Single Dose of Diazapam Rectal Gel (DRG)AUC 0-24h2117.9 ng*h/mLStandard Deviation 996.27
Primary

Cmax

Relative bioavailability based on maximum observed plasma concentration.

Time frame: 24 hours

ArmMeasureValue (MEAN)Dispersion
Single Dose of Diazapam Nasal Spray (DZNS)Cmax157.0 ng/mLStandard Deviation 120.15
Single Dose of Diazapam Rectal Gel (DRG)Cmax309.3 ng/mLStandard Deviation 137.95
Secondary

Focused Nasal Exam (Part A)

A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded none to Grade 4 septal perforation. Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)

Time frame: pre-dose (day 1) up to 24 hours post-dose

Population: Safety population Cohort 1. (Accessed only for DZNS Arm)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part A)Nasal Irritation at Baseline - NONE64 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part A)Grade 1a1 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part A)Grade 1b0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part A)Grade 30 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part A)Grade 30 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part A)Grade 1b0 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part A)Nasal Irritation at Baseline - NONE6 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part A)Grade 1a3 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part A)Grade 1b2 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part A)Grade 1a0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part A)Nasal Irritation at Baseline - NONE0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part A)Grade 30 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part A)Nasal Irritation at Baseline - NONE1 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part A)Grade 1a0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part A)Grade 1b0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part A)Grade 30 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part A)Nasal Irritation at Baseline - NONE0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part A)Grade 31 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part A)Grade 1a0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part A)Grade 1b0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Focused Nasal Exam (Part A)Grade 1a0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Focused Nasal Exam (Part A)Nasal Irritation at Baseline - NONE0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Focused Nasal Exam (Part A)Grade 1b0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Focused Nasal Exam (Part A)Grade 30 Participants
DZNS - At 24 Hours Post-Dose - MissingFocused Nasal Exam (Part A)Grade 1b0 Participants
DZNS - At 24 Hours Post-Dose - MissingFocused Nasal Exam (Part A)Nasal Irritation at Baseline - NONE0 Participants
DZNS - At 24 Hours Post-Dose - MissingFocused Nasal Exam (Part A)Grade 1a0 Participants
DZNS - At 24 Hours Post-Dose - MissingFocused Nasal Exam (Part A)Grade 30 Participants
Secondary

Focused Nasal Exam (Part B)

A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)

Time frame: pre-dose (day 1) up to 24 hours post-dose

Population: The Safety population / Cohort 1. (Accessed only for DZNS Arm)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)At Baseline: Mucosal Erythema - None67 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)At Baseline: Mucosal Edema-None70 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)Mucosal Bleeding/Epistaxis - Mild1 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)At Baseline: Mucosal Bleeding/Epistaxis - None76 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)At Baseline: Nasal Discharge - None67 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)Nasal Discharge - Moderate0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)At Baseline: Crusting of Mucosa - None77 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)Mucosal Edema - Moderate0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)Mucosal Edrythema - Mild0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)Nasal Discharge - Mild1 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Focused Nasal Exam (Part B)Mucosal Edema - Mild1 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)Nasal Discharge - Mild1 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)At Baseline: Mucosal Erythema - None6 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)Nasal Discharge - Moderate1 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)Mucosal Edema - Mild3 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)At Baseline: Mucosal Edema-None3 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)Mucosal Bleeding/Epistaxis - Mild0 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)At Baseline: Mucosal Bleeding/Epistaxis - None1 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)Mucosal Edema - Moderate1 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)At Baseline: Crusting of Mucosa - None1 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)At Baseline: Nasal Discharge - None7 Participants
Single Dose of Diazapam Rectal Gel (DRG)Focused Nasal Exam (Part B)Mucosal Edrythema - Mild5 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)Nasal Discharge - Moderate0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)At Baseline: Mucosal Edema-None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)Mucosal Edema - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)Mucosal Edema - Moderate0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)At Baseline: Nasal Discharge - None1 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)Nasal Discharge - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)At Baseline: Mucosal Erythema - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)Mucosal Edrythema - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)At Baseline: Mucosal Bleeding/Epistaxis - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)Mucosal Bleeding/Epistaxis - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bFocused Nasal Exam (Part B)At Baseline: Crusting of Mucosa - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)At Baseline: Mucosal Erythema - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)At Baseline: Nasal Discharge - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)At Baseline: Mucosal Edema-None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)Mucosal Edrythema - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)Mucosal Edema - Moderate0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)At Baseline: Mucosal Bleeding/Epistaxis - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)Mucosal Edema - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)At Baseline: Crusting of Mucosa - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)Mucosal Bleeding/Epistaxis - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)Nasal Discharge - Moderate0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Focused Nasal Exam (Part B)Nasal Discharge - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)Mucosal Bleeding/Epistaxis - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)At Baseline: Mucosal Erythema - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)At Baseline: Nasal Discharge - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)At Baseline: Mucosal Bleeding/Epistaxis - None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)At Baseline: Mucosal Edema-None0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)Nasal Discharge - Moderate0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)Mucosal Edrythema - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)Mucosal Edema - Moderate0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)Nasal Discharge - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)Mucosal Edema - Mild0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Focused Nasal Exam (Part B)At Baseline: Crusting of Mucosa - None0 Participants
Secondary

Smell Identification Test (SIT)

The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different scratch and sniff strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.

Time frame: day 1 up to day 31

Population: Safety Population / Cohort 1. (Accessed only for DZNS Arm)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Single Dose of Diazapam Nasal Spray (DZNS)Smell Identification Test (SIT)Mild Microsmia2 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Smell Identification Test (SIT)Missing0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Smell Identification Test (SIT)Anosmia0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Smell Identification Test (SIT)At BASELINE: Normosmia19 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Smell Identification Test (SIT)Probable Malingering0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Smell Identification Test (SIT)Severe Microsmia0 Participants
Single Dose of Diazapam Nasal Spray (DZNS)Smell Identification Test (SIT)Moderate Microsmia2 Participants
Single Dose of Diazapam Rectal Gel (DRG)Smell Identification Test (SIT)Probable Malingering0 Participants
Single Dose of Diazapam Rectal Gel (DRG)Smell Identification Test (SIT)At BASELINE: Normosmia10 Participants
Single Dose of Diazapam Rectal Gel (DRG)Smell Identification Test (SIT)Anosmia0 Participants
Single Dose of Diazapam Rectal Gel (DRG)Smell Identification Test (SIT)Mild Microsmia10 Participants
Single Dose of Diazapam Rectal Gel (DRG)Smell Identification Test (SIT)Moderate Microsmia3 Participants
Single Dose of Diazapam Rectal Gel (DRG)Smell Identification Test (SIT)Severe Microsmia1 Participants
Single Dose of Diazapam Rectal Gel (DRG)Smell Identification Test (SIT)Missing0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bSmell Identification Test (SIT)Moderate Microsmia3 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bSmell Identification Test (SIT)Mild Microsmia5 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bSmell Identification Test (SIT)Severe Microsmia1 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bSmell Identification Test (SIT)Anosmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bSmell Identification Test (SIT)Missing0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bSmell Identification Test (SIT)At BASELINE: Normosmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 1bSmell Identification Test (SIT)Probable Malingering0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Smell Identification Test (SIT)Missing0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Smell Identification Test (SIT)Mild Microsmia1 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Smell Identification Test (SIT)Moderate Microsmia6 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Smell Identification Test (SIT)Severe Microsmia4 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Smell Identification Test (SIT)At BASELINE: Normosmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Smell Identification Test (SIT)Probable Malingering0 Participants
DZNS - At 24 Hours Post-Dose - Grade 2Smell Identification Test (SIT)Anosmia2 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Smell Identification Test (SIT)At BASELINE: Normosmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Smell Identification Test (SIT)Anosmia3 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Smell Identification Test (SIT)Missing0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Smell Identification Test (SIT)Mild Microsmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Smell Identification Test (SIT)Moderate Microsmia1 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Smell Identification Test (SIT)Severe Microsmia1 Participants
DZNS - At 24 Hours Post-Dose - Grade 3Smell Identification Test (SIT)Probable Malingering0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Smell Identification Test (SIT)Missing0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Smell Identification Test (SIT)Severe Microsmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Smell Identification Test (SIT)Anosmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Smell Identification Test (SIT)Mild Microsmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Smell Identification Test (SIT)Probable Malingering0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Smell Identification Test (SIT)Moderate Microsmia0 Participants
DZNS - At 24 Hours Post-Dose - Grade 4Smell Identification Test (SIT)At BASELINE: Normosmia0 Participants
DZNS - At 24 Hours Post-Dose - MissingSmell Identification Test (SIT)At BASELINE: Normosmia1 Participants
DZNS - At 24 Hours Post-Dose - MissingSmell Identification Test (SIT)Missing2 Participants
DZNS - At 24 Hours Post-Dose - MissingSmell Identification Test (SIT)Mild Microsmia0 Participants
DZNS - At 24 Hours Post-Dose - MissingSmell Identification Test (SIT)Severe Microsmia0 Participants
DZNS - At 24 Hours Post-Dose - MissingSmell Identification Test (SIT)Anosmia1 Participants
DZNS - At 24 Hours Post-Dose - MissingSmell Identification Test (SIT)Moderate Microsmia0 Participants
DZNS - At 24 Hours Post-Dose - MissingSmell Identification Test (SIT)Probable Malingering0 Participants
Secondary

Taste Change Questionnaire

Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.

Time frame: Up to 24 hours

Population: Safety Population / Cohort 1. (Accessed only for DZNS Arm)

ArmMeasureGroupValue (MEAN)Dispersion
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire5 mins Post-Dose6.5 units on a scaleStandard Deviation 3.57
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire15 mins Post-Dose4.6 units on a scaleStandard Deviation 3.09
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire30 mins Post Dose2.8 units on a scaleStandard Deviation 2.75
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire1 hr Post Dose1.0 units on a scaleStandard Deviation 1.45
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire2 hrs Post-Dose0.3 units on a scaleStandard Deviation 0.48
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire4 hrs Post-Dose0.1 units on a scaleStandard Deviation 0.36
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire8 hrs Post-Dose0.0 units on a scaleStandard Deviation 0
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire12 hrs Post-Dose0.0 units on a scaleStandard Deviation 0
Single Dose of Diazapam Nasal Spray (DZNS)Taste Change Questionnaire24 hrs Post-Dose0.0 units on a scaleStandard Deviation 0

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026